Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.

Clinical pharmacology and therapeutics - 1 Oct 2021

Liu Michelle, Roden Dan M, Peterson Josh F

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19
Share to Genotype
Share to Pharmacogenomic Variants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Platelet Aggregation Inhibitors

Share to Treatment Failure

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 33690885
DOI: 10.1002/cpt.2215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers.PMID 33690885Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Semantic proximity Read ↗

Clopidogrel and CYP2C19 testing: ready for clinical prime time?Semantic proximity Read ↗

Current controversies in the pharmacogenomics of clopidogrel.Semantic proximity Read ↗

Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity Read ↗

The clopidogrel conundrum.Semantic proximity Read ↗

Point-Counterpoint: CYP2C19 Genotyping for Clopidogrel.Semantic proximity Read ↗

Pharmacogenetics of Clopidogrel: An Unresolved Issue.Semantic proximity Read ↗

Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes.Semantic proximity Read ↗

Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.Semantic proximity Read ↗

Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.Semantic proximity Read ↗

Study on the effect of CYP2C19 genetic polymorphism and plasma concentration on clopidogrel resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.